Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)
Clinical trial NCT03410108 · COMPLETED
Trial details
- NCT number
- NCT03410108
- Sponsor
- Takeda
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-01-29
- Primary completion
- 2020-09-29
- Enrollment
- 104
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.